(Q39092056)

9 September 2017

title

The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection (English)

1 reference

9 September 2017

0 references

Rujun Li

1 reference

9 September 2017

Dongfang Tang

1 reference

9 September 2017

Jinshi Zhang

1 reference

9 September 2017

Jinding Wu

1 reference

9 September 2017

Ling Wang

1 reference

9 September 2017

Jun Dong

1 reference

9 September 2017

publication date

25 September 2013

1 reference

Journal of Neuro-Oncology

9 September 2017

published in

1 reference

9 September 2017

volume

116

1 reference

9 September 2017

1 reference

9 September 2017

page(s)

25-30

1 reference

Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Orthotopic model of SHG-44 in the enhanced green fluorescent protein nude mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Temozolomide in the treatment of recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

The safety of the temozolomide in patients with malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Pharmacology of oral chemotherapy agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

PEG400 novel phase description in water

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1255-7

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24065569

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24065569

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Expression of the O6-methylguanine-DNA methyltransferase gene in eight human tumor cell lines

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24065569

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-013-1255-7

1 reference

9 September 2017

1 reference